Inception Return
(10/31/1996)
|
10.54 %
|
|
YTD Return
|
9.80 %
|
|
NAVPS
(5/7/2024)
|
$118.15
|
|
Change
|
$1.43 / 1.23 %
|
|
|
Growth of $10,000
(As of March 31, 2024)
|
|
MER
|
2.72 %
|
|
Assets ($mil)
|
-
|
|
Rank (1Yr)
|
124/173
|
|
Std Dev (3Yr)
|
16.31 %
|
|
Volatility Ranking (3Yr)
|
7/10
|
|
RRSP Eligibility
|
Yes
|
|
Load
|
No Load
|
|
Max Front End
|
-
|
|
Max Back End
|
-
|
|
Sales Status
|
Open
|
|
|
Objective
The fundamental investment objective of the Fund is to achieve long-term capital appreciation by investing primarily in equity securities of companies located in the United States and other countries, that are engaged in the research, development, production, or distribution of products or services related to health care, medicine, or the life sciences.
|
Fund Manager
TD Asset Management Inc.
Portfolio Manager
TD Asset Management Inc.
Sub-Advisor
Ziad Bakri, T. Rowe Price Associates, Inc.
|
|
Asset Allocation
(As of March 31, 2024)
|
Sector Allocation
(As of March 31, 2024)
|
Geographic Allocation
(As of March 31, 2024)
|
Top 10 Holdings
| Name | Asset | Sector | Geographic | Percent |
| Eli Lilly and Co | US Equity | Healthcare | United States | 9.99% |
| UnitedHealth Group Inc | US Equity | Healthcare | United States | 6.14% |
| Intuitive Surgical Inc | US Equity | Healthcare | United States | 4.17% |
| Merck & Co Inc | US Equity | Healthcare | United States | 4.06% |
| Thermo Fisher Scientific Inc | US Equity | Healthcare | United States | 4.05% |
| Stryker Corp | US Equity | Healthcare | United States | 3.66% |
| Elevance Health Inc | US Equity | Healthcare | United States | 3.56% |
| Danaher Corp | US Equity | Healthcare | United States | 2.95% |
| Regeneron Pharmaceuticals Inc | US Equity | Healthcare | United States | 2.70% |
| Vertex Pharmaceuticals Inc | US Equity | Healthcare | United States | 2.12% |
Performance Data
(As of March 31, 2024)
|
|
Return (%)
|
Annualized Return (%)
|
|
Return
|
1
Mth
|
3
Mth
|
6
Mth
|
YTD
|
1
Yr
|
3
Yr
|
5
Yr
|
10
Yr
|
|
Fund
|
1.29
|
9.80
|
14.95
|
9.80
|
12.04
|
3.89
|
7.80
|
11.58
|
|
Benchmark
|
4.14
|
6.62
|
15.26
|
6.62
|
13.96
|
9.11
|
9.96
|
7.67
|
|
Quartile Ranking
|
3
|
2
|
3
|
2
|
3
|
3
|
3
|
2
|
|
Calendar Return (%)
|
2023
|
2022
|
2021
|
2020
|
2019
|
2018
|
2017
|
2016
|
2015
|
2014
|
|
Fund
|
-0.96
|
-7.96
|
9.45
|
24.11
|
20.38
|
7.57
|
17.32
|
-15.15
|
32.78
|
40.68
|
|
Benchmark
|
11.75
|
-5.84
|
25.09
|
5.60
|
22.88
|
-8.89
|
9.10
|
21.08
|
-8.32
|
10.55
|
|
Quartile Ranking
|
4
|
2
|
3
|
3
|
3
|
1
|
3
|
4
|
1
|
1
|